CMS expanded coverage of DNA sequencing for patients with inherited ovarian or breast cancers, the agency said Jan. 27.
The expansion will allow more Medicare patients access to Next Generation Sequencing to reduce mortality and improve health outcomes for inherited cancers. Genetic testing can help patients and their providers better understand what treatments or clinical trials would work best for their cancer cells.
Medicare first started covering laboratory tests using NGS in March 2018 for specific patients with advanced cancer.
More articles on healthcare finance:
Bon Secours to close Kentucky hospital, affecting 1,000 employees
Trump 'going to look' at Medicare cuts
Los Angeles hospital closes after purchase deal falls through